In The Claims:

Upon entry, this listing of claims will replace all prior versions or listings of claims in the present application:

1. (previously presented) A compound having the formula:

wherein B is a purine moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.

2 – 28. (cancelled)

29. (previously presented) A compound having the formula:



wherein B is a purine moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.

30. **(currently amended)** The compound of Claims 1 or 29, wherein B is selected from the group consisting of 6-aminopurine, 2,6-diaminopurine, 2-amino-6-cyclopropylaminopurine, 6-hydroxypurine, 2-amino-6-halo substituted purine, 2-amino-6-alkoxy substituted purine, and 2-amino-6-hydroxypurine. ~~, 3-deazapurine, 7-deazapurine, and 8-azapurine,~~

31. (previously presented) The compounds of Claims 1 or 29, wherein B is selected from the group consisting of adenin-N^9-yl, guanin-N^9-yl, 2,6-diaminopurine-N^9-yl, 2-amino-6-cyclopropylaminopurin-N^9-yl and 2-amino-6-chloropurin-N^9-yl.

32. (previously presented) An antiviral compound selected from the group consisting of syn-N^9-2-hydroxymethylcyclopropylidenemethyl)adenine,

syn-N^9-(2-hydroxymethylcyclopropylidenemethyl)guanine,
syn-2,6-diamino-N^9-2-hydroxymethylcyclo-propylidenemethyl)purine,
syn-2-amino-6-cyclopropylamino-N^9-2-hydroxymethylcyclopropylidenemethyl)purine and pharmaceutically acceptable salts, and prodrugs, thereof.

33. (previously presented) An antiviral compound selected from the group consisting of methyl-phenyl-phosphoro-L-alaninate of syn-N^9-(2-hydroxymethylcyclo-propylidenemethyl)adenine, methyl phenyl-phosphoro-L-alaninate of anti-N^2-(2-hydroxymethylcyclo-propylidenemethyl)adenine and pharmaceutically acceptable salts, and prodrugs, thereof.

34. **(currently amended)** A composition comprising a compound of Claims 1 ~~and~~ or 29 and a pharmaceutically acceptable carrier.

35. **(currently amended)** A method of treating mammals infected with a virus selected from the group consisting of HCMV, HSV-1, HSV-2, HHV-6, HIV, EBV, and HBV comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of Claims 1 ~~and~~ or 29.

36. (original) The method of Claim 35, wherein said mammal is a human.

37. (original) The method of Claim 35, wherein said virus is a human herpes virus.

38. (original) The method of Claim 35, wherein said virus is a human immunodeficiency virus.

39. (original) The method of Claim 35, wherein said virus is hepatitis B virus.

40. (original) The method of Claim 35, further comprising the step of administering an additional antiviral compound.

41. (original) The method of Claim 40, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddI, ddC, d4T, and combinations thereof.

42. (previously presented) The compound having the formula:



wherein B is 2-amino-6-cyclopropylaminopurin-N^9-yl, and pharmaceutically acceptable salts, and prodrugs, thereof.

43. (previously presented) The (S)-(+)-enantiomer of the compound of claim 42.

44. (previously presented) The (R)-(−)-enantiomer of the compound of claim 42.

45. **(currently amended)** A composition comprising a compound of Claims ~~42-44~~ **42, 43, or 44** and a pharmaceutically acceptable carrier.

46. **(currently amended)** A method of treating mammals infected with a virus selected from the group consisting of HCMV, HSV-1, HSV-2, HHV-6, HIV, EBV, and HBV comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of Claims ~~42-44~~ **42, 43, or 44**.